Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
January 22, 2024
At the World Bank-IMF Annual Meetings last fall in Marrakesh, the Bank governors endorsed innovative financial instruments to boost lending at the International Bank for Reconstruction and Development (IBRD)—the Bank’s arm that lends to creditworthy countries. Some donor countries have signaled thei...
Blog Post
November 29, 2023
At the Annual Meetings of the World Bank and IMF in Marrakech in October, the governors of the World Bank agreed upon next steps in the Bank’s “Evolution Roadmap.” The level of ambition is still high, but big reform is far from a done deal. Looking to the past, there has been no shortage of World Ba...
Blog Post
October 10, 2023
One burning question is if the World Bank - together with the regional development banks - will use their potential in decarbonising the world economy. The first step in barricading the gates of hell has to be decarbonising the energy sector. It contributes the most to global greenhouse gas emission...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...